Related references
Note: Only part of the references are listed.AMPA receptor subunit localization in schizophrenia anterior cingulate cortex
Jana L. Benesh et al.
SCHIZOPHRENIA RESEARCH (2022)
Chronic administration of ketamine induces cognitive deterioration by restraining synaptic signaling
Yayan Luo et al.
MOLECULAR PSYCHIATRY (2021)
Cannabidiol Modulates the Motor Profile and NMDA Receptor-related Alterations Induced by Ketamine
Charalampos Brakatselos et al.
NEUROSCIENCE (2021)
Effective determination of the principal non-psychoactive cannabinoids in fiber-type Cannabis sativa L. by UPLC-PDA following a comprehensive design and optimization of extraction methodology
Petros S. Tzimas et al.
ANALYTICA CHIMICA ACTA (2021)
Detrimental effects of adolescent escalating low-dose Δ9-tetrahydrocannabinol leads to a specific bio-behavioural profile in adult male rats
Nafsika Poulia et al.
BRITISH JOURNAL OF PHARMACOLOGY (2021)
Cannabidiol modulation of hippocampal glutamate in early psychosis
Aisling O'Neill et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2021)
Metaplastic Effects of Ketamine and MK-801 on Glutamate Receptors Expression in Rat Medial Prefrontal Cortex and Hippocampus
Alessandro Piva et al.
MOLECULAR NEUROBIOLOGY (2021)
Behavioral and neurobiological changes in a novel mouse model of schizophrenia induced by the combination of cuprizone and MK-801
Zheng-yu Sun et al.
BRAIN RESEARCH BULLETIN (2021)
Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects
A. G. Sartim et al.
NEUROPHARMACOLOGY (2021)
Exogenous GM1 Ganglioside Attenuates Ketamine-Induced Neurocognitive Impairment in the Developing Rat Brain
Chen Meng et al.
ANESTHESIA AND ANALGESIA (2020)
Modulating NMDA receptors to treat MK-801-induced schizophrenic cognition deficit: effects of clozapine combining with PQQ treatment and possible mechanisms of action
Xingqin Zhou et al.
BMC PSYCHIATRY (2020)
Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats
Ewa Kozela et al.
MOLECULAR NEUROBIOLOGY (2020)
Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors
Naielly Rodrigues da Silva et al.
PHARMACOLOGICAL RESEARCH (2020)
MAP/ERK Signaling in Developing Cognitive and Emotional Function and Its Effect on Pathological and Neurodegenerative Processes
Hector Albert-Gasco et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia A Systematic Review and Meta-analysis
Katherine Beck et al.
JAMA NETWORK OPEN (2020)
Cannabidiol inhibits febrile seizure by modulating AMPA receptor kinetics through its interaction with the N-terminal domain of GluA1/GluA2
Yongzhou Yu et al.
PHARMACOLOGICAL RESEARCH (2020)
Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms
Gabriela Pandini Silote et al.
JOURNAL OF CHEMICAL NEUROANATOMY (2019)
Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation
Roger Hudson et al.
JOURNAL OF NEUROSCIENCE (2019)
Ketamine applications beyond anesthesia - A literature review
Agata Nowacka et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics
Fulgencio Ruso-Julve et al.
TRANSLATIONAL PSYCHIATRY (2019)
Effects of Anesthetic Ketamine on Anxiety-Like Behaviour in Rats
Nikolaos Pitsikas et al.
NEUROCHEMICAL RESEARCH (2019)
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
Philip McGuire et al.
AMERICAN JOURNAL OF PSYCHIATRY (2018)
The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects
Chadi G. Abdallah et al.
NEUROPSYCHOPHARMACOLOGY (2018)
Advantages of the Alpha-lipoic Acid Association with Chlorpromazine in a Model of Schizophrenia Induced by Ketamine in Rats: Behavioral and Oxidative Stress evidences
Luis Rafael Leite Sampaio et al.
NEUROSCIENCE (2018)
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Panos Zanos et al.
PHARMACOLOGICAL REVIEWS (2018)
Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy
Allie J. Widman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Olanzapine Reverses MK-801-Induced Cognitive Deficits and Region-Specific Alterations of NMDA Receptor Subunits
Xiao Liu et al.
FRONTIERS IN BEHAVIORAL NEUROSCIENCE (2018)
Chronic MK-801 Application in Adolescence and Early Adulthood: A Spatial Working Memory Deficit in Adult Long-Evans Rats But No Changes in the Hippocampal NMDA Receptor Subunits
Libor Uttl et al.
FRONTIERS IN PHARMACOLOGY (2018)
The extracellular signal-regulated kinase 1/2 pathway in neurological diseases: A potential therapeutic target
Jing Sun et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2017)
Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model
Ashleigh L. Osborne et al.
NEUROPSYCHOPHARMACOLOGY (2017)
Glutamate Deregulation in Ketamine-Induced Psychosis-A Potential Role of PSD95, NMDA Receptor and PMCA Interaction
Malwina Lisek et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2017)
Pharmacokinetic and behavioural profile of THC, CBD, and THC plus CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC
Tomas Hlozek et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2017)
NMDAR dependent intracellular responses associated with cocaine conditioned place preference behavior
Stephanie K. Nygard et al.
BEHAVIOURAL BRAIN RESEARCH (2017)
Therapeutic Potential of Cannabinoids in Psychosis
F. Markus Leweke et al.
BIOLOGICAL PSYCHIATRY (2016)
Pro-Cognitive Action of CART Is Mediated via ERK in the Hippocampus
Ashish P. Bharne et al.
HIPPOCAMPUS (2016)
Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a NovelmTOR/p70S6Kinase Signaling Pathway
Justine Renard et al.
JOURNAL OF NEUROSCIENCE (2016)
Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors
Raquel Linge et al.
NEUROPHARMACOLOGY (2016)
Different dosing regimens of repeated ketamine administration have opposite effects on novelty processing in rats
Anett Schumacher et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2016)
Changes in hippocampal AMPA receptors and cognitive impairments in chronic ketamine addiction models: another understanding of ketamine CNS toxicity
Runtao Ding et al.
SCIENTIFIC REPORTS (2016)
Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence
Cathrin Rohleder et al.
FRONTIERS IN PHARMACOLOGY (2016)
Reviewing the ketamine model for schizophrenia
Joel Frohlich et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2014)
Metaplastic effects of subanesthetic ketamine on CA1 hippocampal function
Yukitoshi Izumi et al.
NEUROPHARMACOLOGY (2014)
Crocins, the active constituents of Crocus Sativus L., counteracted ketamine-induced behavioural deficits in rats
Georgia Georgiadou et al.
PSYCHOPHARMACOLOGY (2014)
Interaction Between αCaMKII and GluN2B Controls ERK-Dependent Plasticity
Farida El Gaamouch et al.
JOURNAL OF NEUROSCIENCE (2012)
Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats
Anand Gururajan et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine- induced psychopathology
J. M. Stone et al.
MOLECULAR PSYCHIATRY (2012)
Distinct Neurobehavioural Effects of Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice
Leonora E. Long et al.
PLOS ONE (2012)
Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats
Agnieszka Nikiforuk et al.
PSYCHOPHARMACOLOGY (2012)
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
F. M. Leweke et al.
TRANSLATIONAL PSYCHIATRY (2012)
Δ9-THC and WIN55,212-2 affect brain tissue levels of excitatory amino acids in a phenotype-, compound-, dose-, and region-specific manner
A. Galanopoulos et al.
BEHAVIOURAL BRAIN RESEARCH (2011)
Effect of cannabidiol in a MK-801-rodent model of aspects of Schizophrenia
Anand Gururajan et al.
BEHAVIOURAL BRAIN RESEARCH (2011)
Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania
Samira S. Valvassori et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
NMDA Receptor Hypofunction Phase Couples Independent gamma-Oscillations in the Rat Visual Cortex
Himashi Anver et al.
NEUROPSYCHOPHARMACOLOGY (2011)
COMPLEX RECEPTOR MEDIATION OF ACUTE KETAMINE APPLICATION ON IN VITRO GAMMA OSCILLATIONS IN MOUSE PREFRONTAL CORTEX: MODELING GAMMA BAND OSCILLATION ABNORMALITIES IN SCHIZOPHRENIA
J. M. McNally et al.
NEUROSCIENCE (2011)
MECHANISMS UNDERLYING KETAMINE-INDUCED SYNAPTIC DEPRESSION IN RAT HIPPOCAMPUS-MEDIAL PREFRONTAL CORTEX PATHWAY
H. Kamiyama et al.
NEUROSCIENCE (2011)
A behavioural comparison of acute and chronic Δ9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice
Leonora E. Long et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia
Axel Becker et al.
PSYCHOPHARMACOLOGY (2009)
Increased response to ketamine following treatment at long intervals: Implications for intermittent use
Keith A. Trujillo et al.
BIOLOGICAL PSYCHIATRY (2008)
Rapid cortico-limbic alterations in AMPA receptor densities after administration of PCP: Implications for schizophrenia
Katerina Zavitsanou et al.
JOURNAL OF CHEMICAL NEUROANATOMY (2008)
Differential regulation of the NMDA receptor by acute and sub-chronic phencyclidine administration in the developing rat
Noelle C. Anastasio et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity
Koji Yashiro et al.
NEUROPHARMACOLOGY (2008)
Activity-dependent regulation of NR2B translation contributes to metaplasticity in mouse visual cortex
Wendy S. Chen et al.
NEUROPHARMACOLOGY (2007)
Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia
L. V. Kristiansen et al.
MOLECULAR PSYCHIATRY (2006)
The effects of MK-801 on the phosphorylation of Ser338-c-Raf-MEK-ERK pathway in the rat frontal cortex
Yong Min Ahn et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2006)
Schizophrenia-relevant behavioral testing in rodent models: A uniquely human disorder?
Craig M. Powell et al.
BIOLOGICAL PSYCHIATRY (2006)
Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia
HT Mueller et al.
MOLECULAR BRAIN RESEARCH (2004)
The role of the extracellular signal-regulated kinase pathway in cerebellar abnormalities in schizophrenia
SV Kyosseva
CEREBELLUM (2004)
Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia
A Becker et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2003)
Effects of ketamine in normal and schizophrenic volunteers
AC Lahti et al.
NEUROPSYCHOPHARMACOLOGY (2001)
Share Paper
